Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 5.4.2.11 - phosphoglycerate mutase (2,3-diphosphoglycerate-dependent)

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Adenocarcinoma
An allosteric PGAM1 inhibitor effectively suppresses pancreatic ductal adenocarcinoma.
Identification of PGAM1 as a putative therapeutic target for pancreatic ductal adenocarcinoma metastasis using quantitative proteomics.
Phosphoglycerate mutase 1(PGAM1) promotes pancreatic ductal adenocarcinoma (PDAC) metastasis by acting as a novel downstream target of PI3K/Akt/mTOR pathway.
Adenocarcinoma of Lung
Phosphoglycerate mutase, 2,3-bisphosphoglycerate phosphatase and enolase activity and isoenzymes in lung, colon and liver carcinomas.
Anemia
Phosphoglycerate mutase BB isoenzyme deficiency in a patient with non-spherocytic anemia: familial and metabolic studies.
Astrocytoma
Phosphoglycerate mutase 1 is highly expressed in C6 glioma cells and human astrocytoma.
Phosphoglycerate mutase, 2,3-bisphosphoglycerate phosphatase and creatine kinase activity and isoenzymes in human brain tumours.
Ataxia Telangiectasia
Phosphoglycerate mutase 1 (PGAM1) overexpression promotes radio- and chemoresistance in gliomas by activating the DNA damage response.
Atherosclerosis
Proteomic characterization of rat liver exposed to 2,3,7,8-tetrachlorobenzo-p-dioxin.
Brain Neoplasms
Phosphoglycerate mutase, 2,3-bisphosphoglycerate phosphatase and creatine kinase activity and isoenzymes in human brain tumours.
Breast Neoplasms
Phosphoglycerate mutase 1 promotes cancer cell migration independent of its metabolic activity.
Phosphoglycerate mutase 1 regulates dNTP pool and promotes homologous recombination repair in cancer cells.
Phosphoglycerate mutase, 2,3-bisphosphoglycerate phosphatase, creatine kinase and enolase activity and isoenzymes in breast carcinoma.
Prognostic Value of a Glycolytic Signature and Its Regulation by Y-Box-Binding Protein 1 in Triple-Negative Breast Cancer.
The diagnostic value and functional roles of phosphoglycerate mutase 1 in glioma.
Candidiasis
Phagocytes from Mice Lacking the Sts Phosphatases Have an Enhanced Antifungal Response to Candida albicans.
Carcinogenesis
PGAM1, regulated by miR-3614-5p, functions as an oncogene by activating transforming growth factor-? (TGF-?) signaling in the progression of non-small cell lung carcinoma.
Phosphoglycerate mutase 1 is highly expressed in C6 glioma cells and human astrocytoma.
Phosphoglyceric acid mutase-1 contributes to oncogenic mTOR-mediated tumor growth and confers non-small cell lung cancer patients with poor prognosis.
Carcinoid Tumor
Phosphoglycerate mutase, 2,3-bisphosphoglycerate phosphatase and enolase activity and isoenzymes in lung, colon and liver carcinomas.
Carcinoma
Erratum: Phosphoglycerate Mutase 1 Predicts the Poor Prognosis of Oral Squamous Cell Carcinoma and is Associated with Cell Migration - Erratum.
Expression of PGAM1 in renal clear cell carcinoma and its clinical significance.
Insulin/IGF1-PI3K-dependent nucleolar localization of a glycolytic enzyme--phosphoglycerate mutase 2, is necessary for proper structure of nucleolus and RNA synthesis.
PGAM1 and TP53 mRNA levels in canine mammary carcinomas - Short communication.
PGAM1, regulated by miR-3614-5p, functions as an oncogene by activating transforming growth factor-? (TGF-?) signaling in the progression of non-small cell lung carcinoma.
Phosphoglycerate Mutase 1 Predicts the Poor Prognosis of Oral Squamous Cell Carcinoma and is Associated with Cell Migration.
Phosphoglycerate mutase, 2,3-bisphosphoglycerate phosphatase and enolase activity and isoenzymes in lung, colon and liver carcinomas.
Carcinoma, Hepatocellular
Evaluation of nuclear PGAM2 value in hepatocellular carcinoma prognosis.
Quantitative proteomics identification of phosphoglycerate mutase 1 as a novel therapeutic target in hepatocellular carcinoma.
Carcinoma, Non-Small-Cell Lung
HKB99, an allosteric inhibitor of phosphoglycerate mutase 1, suppresses invasive pseudopodia formation and upregulates plasminogen activator inhibitor-2 in erlotinib-resistant non-small cell lung cancer cells.
PGAM1, regulated by miR-3614-5p, functions as an oncogene by activating transforming growth factor-? (TGF-?) signaling in the progression of non-small cell lung carcinoma.
Phosphoglyceric acid mutase-1 contributes to oncogenic mTOR-mediated tumor growth and confers non-small cell lung cancer patients with poor prognosis.
Carcinoma, Renal Cell
Expression of PGAM1 in renal clear cell carcinoma and its clinical significance.
Carcinoma, Squamous Cell
Insulin/IGF1-PI3K-dependent nucleolar localization of a glycolytic enzyme--phosphoglycerate mutase 2, is necessary for proper structure of nucleolus and RNA synthesis.
Phosphoglycerate mutase, 2,3-bisphosphoglycerate phosphatase and enolase activity and isoenzymes in lung, colon and liver carcinomas.
Cataract
In vivo substrates of the lens molecular chaperones ?A-crystallin and ?B-crystallin.
Central Nervous System Diseases
High prevalence of autoantibodies against phosphoglycerate mutase 1 in patients with autoimmune central nervous system diseases.
Contracture
Phosphoglycerate mutase deficiency (glycogen storage disease X) caused by a novel variant in PGAM-M.
Diabetic Neuropathies
Partial deficiency of phosphoglycerate mutase with diabetic polyneuropathy: the first Japanese patient.
Endometrial Neoplasms
A proteomic approach for the identification of biomarkers in endometrial cancer uterine aspirate.
fructose-bisphosphatase deficiency
Effect of phosphoglycerate mutase and fructose 1,6-bisphosphatase deficiency on symbiotic Burkholderia phymatum.
fructose-bisphosphate aldolase deficiency
Tarui disease and distal glycogenoses: clinical and genetic update.
Glioblastoma
Phosphoglycerate mutase, 2,3-bisphosphoglycerate phosphatase and creatine kinase activity and isoenzymes in human brain tumours.
Glioma
A new potential anti-cancer beta-carboline derivative decreases the expression levels of key proteins involved in glioma aggressiveness: A proteomic investigation.
Correlation of expression levels of ANXA2, PGAM1, and CALR with glioma grade and prognosis.
Phosphoglycerate mutase 1 (PGAM1) overexpression promotes radio- and chemoresistance in gliomas by activating the DNA damage response.
Phosphoglycerate Mutase 1 Activates DNA Damage Repair via Regulation of WIP1 Activity.
Phosphoglycerate mutase 1 is highly expressed in C6 glioma cells and human astrocytoma.
Quantitative proteomic analysis of global effect of LLL12 on U87 cell's proteome: An insight into the molecular mechanism of LLL12.
The diagnostic value and functional roles of phosphoglycerate mutase 1 in glioma.
[Proteomic analysis of rat astrocytes and C6 glioma cells]
Glycogen Storage Disease
Clinical application of massively parallel sequencing in the molecular diagnosis of glycogen storage diseases of genetically heterogeneous origin.
Metabolic myopathies.
Novel heterozygous mutations in the PGAM2 gene with negative exercise testing.
Targeted exome sequencing identified a novel frameshift variant in the PGAM2 gene causing glycogen storage disease type X.
Tarui disease and distal glycogenoses: clinical and genetic update.
Glycogen Storage Disease Type V
A nonischemic forearm exercise test for McArdle disease.
Graves Disease
Identification Of New Rare Variants Associated With Familial Autoimmune Thyroid Diseases By Deep Sequencing Of Linked Loci.
Heart Failure
Phosphoglycerate mutase 2 is elevated in serum of patients with heart failure and correlates with the disease severity and patient's prognosis.
Hepatitis, Autoimmune
Serum proteomic-based analysis for the identification of a potential serological marker for autoimmune hepatitis.
Hyperthyroidism
Proteomic characterization of rat liver exposed to 2,3,7,8-tetrachlorobenzo-p-dioxin.
Infections
Comparative proteome analysis of splenic lymphocytes in senescence-accelerated mice.
Current progress in proteomic study of hepatitis C virus-related human hepatocellular carcinoma.
Enhanced response of T cells from murine gammaherpesvirus 68-infected mice lacking the suppressor of T cell receptor signaling molecules Sts-1 and Sts-2.
Metal-independent variants of phosphoglycerate mutase promote resistance to nutritional immunity and retention of glycolysis during infection.
Papillomavirus can be transmitted through the blood and produce infections in blood recipients: Evidence from two animal models.
Protection from systemic Candida albicans infection by inactivation of the Sts phosphatases.
Recombinant Toxoplasma gondii phosphoglycerate mutase 2 confers protective immunity against toxoplasmosis in BALB/c mice.
Structural and Functional Characterization of the Histidine Phosphatase Domains of Human Sts-1 and Sts-2.
l-lactate dehydrogenase deficiency
Myopathies due to enzyme deficiencies.
Phosphoglycerate kinase deficiency: another cause of recurrent myoglobinuria.
Leiomyoma
Identification of proteins with different abundance associated with cell migration and proliferation in leiomyoma interstitial fluid by proteomics.
Liver Cirrhosis
Evaluation of nuclear PGAM2 value in hepatocellular carcinoma prognosis.
Liver Neoplasms
Quantitative proteomics identification of phosphoglycerate mutase 1 as a novel therapeutic target in hepatocellular carcinoma.
Lung Neoplasms
A Novel Allosteric Inhibitor of Phosphoglycerate Mutase 1 Suppresses Growth and Metastasis of Non-Small-Cell Lung Cancer.
HKB99, an allosteric inhibitor of phosphoglycerate mutase 1, suppresses invasive pseudopodia formation and upregulates plasminogen activator inhibitor-2 in erlotinib-resistant non-small cell lung cancer cells.
Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene.
PGAM1, regulated by miR-3614-5p, functions as an oncogene by activating transforming growth factor-? (TGF-?) signaling in the progression of non-small cell lung carcinoma.
Phosphoglyceric acid mutase-1 contributes to oncogenic mTOR-mediated tumor growth and confers non-small cell lung cancer patients with poor prognosis.
Lymphatic Metastasis
Phosphoglycerate Mutase 1 Predicts the Poor Prognosis of Oral Squamous Cell Carcinoma and is Associated with Cell Migration.
Malaria
Virtual Screening, Molecular Dynamics and ADME-Tox Tools for Finding Potential Inhibitors of Phosphoglycerate Mutase 1 from Plasmodium falciparum.
Menkes Kinky Hair Syndrome
A phosphoglycerate mutase brain isoform (PGAM 1) pseudogene is localized within the human Menkes disease gene (ATP7 A).
Mitochondrial Myopathies
Metabolic myopathies.
Mouth Neoplasms
Metabolic Regulation of Glycolysis and AMP Activated Protein Kinase Pathways during Black Raspberry-Mediated Oral Cancer Chemoprevention.
Multiple Sclerosis
High prevalence of autoantibodies against phosphoglycerate mutase 1 in patients with autoimmune central nervous system diseases.
Muscle Cramp
Exercise-induced cramp, myoglobinuria, and tubular aggregates in phosphoglycerate mutase deficiency.
Molecular basis of muscle phosphoglycerate mutase (PGAM-M) deficiency in the Italian kindred.
Muscle phosphoglycerate mutase deficiency with tubular aggregates: effect of dantrolene.
Muscle phosphoglycerate mutase deficiency: a study of a family with metabolic myopathy.
Muscular Diseases
Effect of fuels on exercise capacity in muscle phosphoglycerate mutase deficiency.
Genomic analysis of five chromosome 7p deletion patients with Greig cephalopolysyndactyly syndrome (GCPS).
Human muscle phosphoglycerate mutase deficiency: newly discovered metabolic myopathy.
Isozyme patterns and protein profiles in neuromuscular disorders.
Manifesting heterozygotes in a Japanese family with a novel mutation in the muscle-specific phosphoglycerate mutase (PGAM-M) gene.
Muscle phosphoglycerate mutase deficiency: a study of a family with metabolic myopathy.
Phosphoglycerate mutase deficiency (glycogen storage disease X) caused by a novel variant in PGAM-M.
Phosphoglycerate mutase deficiency with tubular aggregates in a patient from Panama.
Physiologic assessment of phosphoglycerate mutase deficiency: incremental exercise test.
Unusual presentation of phosphoglycerate mutase deficiency due to two different mutations in PGAM-M gene.
Muscular Dystrophies
Plasma phosphoglycerate mutase as a marker of muscular dystrophy.
Muscular Dystrophy, Duchenne
Plasma phosphoglycerate mutase as a marker of muscular dystrophy.
Myalgia
Muscle phosphoglycerate mutase deficiency: a study of a family with metabolic myopathy.
Unusual presentation of phosphoglycerate mutase deficiency due to two different mutations in PGAM-M gene.
Myocardial Infarction
Activity of phosphoglycerate mutase and its isoenzymes in serum after acute myocardial infarction.
Inactivation of phosphoglycerate mutase and creatine kinase isoenzymes in human serum.
PGAM1 deficiency ameliorates myocardial infarction remodeling by targeting TGF-? via the suppression of inflammation, apoptosis and fibrosis.
Myoglobinuria
Exercise-induced cramp, myoglobinuria, and tubular aggregates in phosphoglycerate mutase deficiency.
Metabolic causes of myoglobinuria.
Metabolic myopathies.
Molecular basis of muscle phosphoglycerate mutase (PGAM-M) deficiency in the Italian kindred.
Muscle phosphoglycerate mutase (PGAM) deficiency: a second case.
Muscle phosphoglycerate mutase deficiency: a study of a family with metabolic myopathy.
Novel heterozygous mutations in the PGAM2 gene with negative exercise testing.
Phosphoglycerate kinase deficiency: another cause of recurrent myoglobinuria.
Phosphoglycerate mutase deficiency (glycogen storage disease X) caused by a novel variant in PGAM-M.
Physiologic assessment of phosphoglycerate mutase deficiency: incremental exercise test.
Unusual presentation of phosphoglycerate mutase deficiency due to two different mutations in PGAM-M gene.
[Myoglobinuria due to enzyme abnormalities in glycolytic pathway--especially lactate dehydrogenase M subunit deficiency]
Neoplasm Metastasis
A Novel Allosteric Inhibitor of Phosphoglycerate Mutase 1 Suppresses Growth and Metastasis of Non-Small-Cell Lung Cancer.
Identification of PGAM1 as a putative therapeutic target for pancreatic ductal adenocarcinoma metastasis using quantitative proteomics.
In silico-based identification of phytochemicals as novel human phosphoglycerate mutase 1 (PGAM1) inhibitors for cancer therapy.
Phosphoglycerate mutase 1 promotes cancer cell migration independent of its metabolic activity.
Phosphoglycerate mutase 1(PGAM1) promotes pancreatic ductal adenocarcinoma (PDAC) metastasis by acting as a novel downstream target of PI3K/Akt/mTOR pathway.
Phosphoglycerate Mutase 1: Its Glycolytic and Non-Glycolytic Roles in Tumor Malignant Behaviors and Potential Therapeutic Significance.
Neoplasms
A Novel Allosteric Inhibitor of Phosphoglycerate Mutase 1 Suppresses Growth and Metastasis of Non-Small-Cell Lung Cancer.
Advances in the proteomic discovery of novel therapeutic targets in cancer.
An allosteric PGAM1 inhibitor effectively suppresses pancreatic ductal adenocarcinoma.
Association of C-terminal region of phosphoglycerate mutase with glycolytic complex regulates energy production in cancer cells.
Characterization of genetically modified mice for phosphoglycerate mutase, a vitally-essential enzyme in glycolysis.
Conformation and dynamics of the C-terminal region in human phosphoglycerate mutase 1.
Correction: Phosphoglycerate mutase 1 promotes cancer cell migration independent of its metabolic activity.
Correction: Phosphoglycerate mutase 1 regulates dNTP pool and promotes homologous recombination repair in cancer cells.
Deacetylation of phosphoglycerate mutase in its distinct central region by SIRT2 down-regulates its enzymatic activity.
Design, synthesis, and biological evaluation of 1,3,6,7-tetrahydroxyxanthone derivatives as phosphoglycerate mutase 1 inhibitors.
Development of Anthraquinone Analogues as Phosphoglycerate Mutase 1 Inhibitors.
Emerging concepts in bioenergetics and cancer research: metabolic flexibility, coupling, symbiosis, switch, oxidative tumors, metabolic remodeling, signaling and bioenergetic therapy.
EPA and DHA attenuate deoxynivalenol-induced intestinal porcine epithelial cell injury and protect barrier function integrity by inhibiting necroptosis signaling pathway.
Evaluation of nuclear PGAM2 value in hepatocellular carcinoma prognosis.
Evidence for an alternative glycolytic pathway in rapidly proliferating cells.
Expression of PGAM1 in renal clear cell carcinoma and its clinical significance.
Histone acetyltransferase 1 is a succinyltransferase for histones and non-histones and promotes tumorigenesis.
Identification of Epigallocatechin-3- Gallate as an Inhibitor of Phosphoglycerate Mutase 1.
Immunohistochemical localization of Phosphoglycerate mutase in capillary endothelium of the brain and periphery.
In Silico Drug Screening Analysis against the Overexpression of PGAM1 Gene in Different Cancer Treatments.
In silico-based identification of phytochemicals as novel human phosphoglycerate mutase 1 (PGAM1) inhibitors for cancer therapy.
Insulin/IGF1-PI3K-dependent nucleolar localization of a glycolytic enzyme--phosphoglycerate mutase 2, is necessary for proper structure of nucleolus and RNA synthesis.
Metabolic shift to serine biosynthesis through 3-PG accumulation and PHGDH induction promotes tumor growth in pancreatic cancer.
Molecular dynamics simulation reveals how phosphorylation of tyrosine 26 of phosphoglycerate mutase 1 upregulates glycolysis and promotes tumor growth.
Multiplexed Autoantibody Signature for Serological Detection of Canine Mammary Tumours.
Off-target effects related to the phosphorothioate modification of nucleic acids.
Oxidative stress activates SIRT2 to deacetylate and stimulate phosphoglycerate mutase.
Papillomavirus can be transmitted through the blood and produce infections in blood recipients: Evidence from two animal models.
PGAM1 and TP53 mRNA levels in canine mammary carcinomas - Short communication.
PGAM1, regulated by miR-3614-5p, functions as an oncogene by activating transforming growth factor-? (TGF-?) signaling in the progression of non-small cell lung carcinoma.
PGAMgnam style: a glycolytic switch controls biosynthesis.
Phosphoglycerate Mutase 1 Activates DNA Damage Repair via Regulation of WIP1 Activity.
Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth.
Phosphoglycerate mutase 1 in cancer: A promising target for diagnosis and therapy.
Phosphoglycerate mutase 1 is highly expressed in C6 glioma cells and human astrocytoma.
Phosphoglycerate mutase 1 knockdown inhibits prostate cancer cell growth, migration, and invasion.
Phosphoglycerate Mutase 1 Predicts the Poor Prognosis of Oral Squamous Cell Carcinoma and is Associated with Cell Migration.
Phosphoglycerate mutase 1 promotes cancer cell migration independent of its metabolic activity.
Phosphoglycerate mutase 1 regulates dNTP pool and promotes homologous recombination repair in cancer cells.
Phosphoglycerate Mutase 1: Its Glycolytic and Non-Glycolytic Roles in Tumor Malignant Behaviors and Potential Therapeutic Significance.
Phosphoglycerate mutase, 2,3-bisphosphoglycerate phosphatase and enolase activity and isoenzymes in lung, colon and liver carcinomas.
Phosphoglycerate mutase, 2,3-bisphosphoglycerate phosphatase, creatine kinase and enolase activity and isoenzymes in breast carcinoma.
Phosphoglyceric acid mutase-1 contributes to oncogenic mTOR-mediated tumor growth and confers non-small cell lung cancer patients with poor prognosis.
Protection from oxidative stress by enhanced glycolysis; a possible mechanism of cellular immortalization.
Proteomic analysis of secreted proteins of non-small cell lung cancer.
Proteomics Approach of Rapamycin Anti-Tumoral Effect on Primary and Metastatic Canine Mammary Tumor Cells In Vitro.
Proteomics identification of PGAM1 as a potential therapeutic target for urothelial bladder cancer.
Shutting down the power supply for DNA repair in cancer cells.
Simultaneous determination of multiple intracellular primary metabolites by ultrahigh performance liquid chromatography coupled with a Q Exactive HF mass spectrometer.
Synthesis and biological evaluation of anthraquinone derivatives as allosteric phosphoglycerate mutase 1 inhibitors for cancer treatment.
Target discovery in small-molecule cell-based screens by in situ proteome reactivity profiling.
The CIMP-high phenotype is associated with energy metabolism alterations in colon adenocarcinoma.
The Design and Synthesis of N-Xanthone Benzenesulfonamides as Novel Phosphoglycerate Mutase 1 (PGAM1) Inhibitors.
The diagnostic value and functional roles of phosphoglycerate mutase 1 in glioma.
The role of phosphoglycerate mutase 1 in tumor aerobic glycolysis and its potential therapeutic implications.
Tyr26 phosphorylation of PGAM1 provides a metabolic advantage to tumours by stabilizing the active conformation.
Xanthone derivatives as phosphoglycerate mutase 1 inhibitors: Design, synthesis, and biological evaluation.
Neuroinflammatory Diseases
Phosphoglycerate Mutase 1 Prevents Neuronal Death from Ischemic Damage by Reducing Neuroinflammation in the Rabbit Spinal Cord.
Oligospermia
PGAM1 knockdown is associated with busulfan?induced hypospermatogenesis and spermatogenic cell apoptosis.
Pancreatic Neoplasms
Identification of PGAM1 as a putative therapeutic target for pancreatic ductal adenocarcinoma metastasis using quantitative proteomics.
Phosphoglycerate mutase 1(PGAM1) promotes pancreatic ductal adenocarcinoma (PDAC) metastasis by acting as a novel downstream target of PI3K/Akt/mTOR pathway.
Phenylketonurias
Altered brain protein expression profiles are associated with molecular neurological dysfunction in the PKU mouse model.
phosphoglycerate kinase deficiency
Phosphoglycerate kinase deficiency: another cause of recurrent myoglobinuria.
phosphoglycerate mutase (2,3-diphosphoglycerate-dependent) deficiency
A nonischemic forearm exercise test for McArdle disease.
Effect of fuels on exercise capacity in muscle phosphoglycerate mutase deficiency.
Effect of phosphoglycerate mutase deficiency on heterotrophic and autotrophic carbon metabolism of Alcaligenes eutrophus.
Exercise-induced cramp, myoglobinuria, and tubular aggregates in phosphoglycerate mutase deficiency.
Glycolytic defects in muscle: aspects of collaboration between basic science and clinical medicine.
Human muscle phosphoglycerate mutase deficiency: newly discovered metabolic myopathy.
Muscle phosphoglycerate mutase deficiency revisited.
Muscle phosphoglycerate mutase deficiency with tubular aggregates: effect of dantrolene.
Muscle phosphoglycerate mutase deficiency.
Muscle phosphoglycerate mutase deficiency: a study of a family with metabolic myopathy.
PGAM1 deficiency ameliorates myocardial infarction remodeling by targeting TGF-? via the suppression of inflammation, apoptosis and fibrosis.
Phosphoglycerate mutase deficiency (glycogen storage disease X) caused by a novel variant in PGAM-M.
Phosphoglycerate mutase deficiency with tubular aggregates in a patient from Panama.
Phosphoglycerate mutase deficiency: case report of a manifesting heterozygote with a novel E154K mutation and very late onset.
Phosphorus magnetic resonance spectroscopy of partially blocked muscle glycolysis. An in vivo study of phosphoglycerate mutase deficiency.
Physiologic assessment of phosphoglycerate mutase deficiency: incremental exercise test.
Progress and problems in muscle glycogenoses.
T cell-specific deletion of Pgam1 reveals a critical role for glycolysis in T cell responses.
Unusual presentation of phosphoglycerate mutase deficiency due to two different mutations in PGAM-M gene.
[Muscle phosphoglycerate mutase deficiency]
[Phosphoglycerate mutase deficiency]
Pre-Eclampsia
Differential proteomic analysis of highly purified placental cytotrophoblasts in preeclampsia demonstrates a state of increased oxidative stress and reduced cytotrophoblast antioxidant defense.
Prolactinoma
PGAM5-CypD pathway is involved in bromocriptine-induced RIP3/MLKL-dependent necroptosis of prolactinoma cells.
Prostatic Neoplasms
Phosphoglycerate mutase 1 knockdown inhibits prostate cancer cell growth, migration, and invasion.
Resveratrol-induced cell growth inhibition and apoptosis is associated with modulation of phosphoglycerate mutase B in human prostate cancer cells: two-dimensional sodium dodecyl sulfate-polyacrylamide gel electrophoresis and mass spectrometry evaluation.
Reperfusion Injury
MiR-330-3p suppresses phosphoglycerate mutase family member 5 -inducted mitophagy to alleviate hepatic ischemia-reperfusion injury.
Sarcoma, Avian
Phosphorylation sites in enolase and lactate dehydrogenase utilized by tyrosine protein kinases in vivo and in vitro.
Seizures
Peony root extract upregulates transthyretin and phosphoglycerate mutase in mouse cobalt focus seizure.
Squamous Cell Carcinoma of Head and Neck
Erratum: Phosphoglycerate Mutase 1 Predicts the Poor Prognosis of Oral Squamous Cell Carcinoma and is Associated with Cell Migration - Erratum.
Phosphoglycerate Mutase 1 Predicts the Poor Prognosis of Oral Squamous Cell Carcinoma and is Associated with Cell Migration.
Starvation
Metabolic shift to serine biosynthesis through 3-PG accumulation and PHGDH induction promotes tumor growth in pancreatic cancer.
Stroke
A new stroke marker as detected by serum phosphoglycerate mutase B-type isozyme.
Thyroiditis
Identification Of New Rare Variants Associated With Familial Autoimmune Thyroid Diseases By Deep Sequencing Of Linked Loci.
Toxoplasmosis
Recombinant Toxoplasma gondii phosphoglycerate mutase 2 confers protective immunity against toxoplasmosis in BALB/c mice.
Tuberculosis
Cloning, expression, purification and preliminary crystallographic data for Rv3214 (EntD), a predicted cofactor-dependent phosphoglycerate mutase from Mycobacterium tuberculosis.
Mycobacterium tuberculosis Rv2419c, the missing glucosyl-3-phosphoglycerate phosphatase for the second step in methylglucose lipopolysaccharide biosynthesis.
Structural and functional analysis of Rv3214 from Mycobacterium tuberculosis, a protein with conflicting functional annotations, leads to its characterization as a phosphatase.
The 1.70 angstroms X-ray crystal structure of Mycobacterium tuberculosis phosphoglycerate mutase.
udp-galactopyranose mutase deficiency
Phosphorus magnetic resonance spectroscopy of partially blocked muscle glycolysis. An in vivo study of phosphoglycerate mutase deficiency.
Urinary Bladder Neoplasms
Proteomics identification of PGAM1 as a potential therapeutic target for urothelial bladder cancer.